Provectus (PVCT) Biopharmaceuticals announced a $3M seed financing round for VisiRose, Provectus’s Founded Entity that is developing novel ocular therapeutics. VisiRose is a newly launched, privately held, clinical-stage biotechnology company focused on initially commercializing Rose Bengal Photodynamic Antimicrobial Therapy for the treatment of infectious keratitis and other eye infections using Provectus’s bioactive synthetic small molecule and active pharmaceutical ingredient Rose Bengal Sodium.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVCT: